| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
92.46(B) |
| Last
Volume: |
505,652 |
Avg
Vol: |
771,513 |
| 52
Week Range: |
$692.45 - $993.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
41,535 |
84,942 |
120,451 |
283,828 |
| Total Sell Value |
$39,627,604 |
$77,255,398 |
$106,928,922 |
$220,981,114 |
| Total People Sold |
9 |
13 |
15 |
17 |
| Total Sell Transactions |
21 |
38 |
54 |
116 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bassler Bonnie L |
Director |
– • – |
2023-03-24 |
4 |
AS |
$818.00 |
$1,014,320 |
D/D |
(1,240) |
1,247 |
|
-6% |
|
| Bassler Bonnie L |
Director |
– • – |
2023-03-24 |
4 |
OE |
$380.95 |
$472,378 |
D/D |
1,240 |
2,487 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2023-03-23 |
4 |
D |
$801.59 |
$5,404,320 |
D/D |
(6,742) |
27,471 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2023-03-23 |
4 |
OE |
$270.43 |
$2,704,300 |
D/D |
10,000 |
34,213 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2023-03-23 |
4 |
AS |
$800.59 |
$2,940,374 |
I/I |
(3,656) |
196,848 |
|
-9% |
|
| Vagelos P Roy |
Director |
– • – |
2023-03-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
312,578 |
|
- |
|
| Fenimore Christopher R. |
SVP Controller |
• – – |
2023-03-23 |
4 |
AS |
$806.47 |
$1,767,782 |
D/D |
(2,192) |
18,409 |
|
-9% |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2023-03-10 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,006 |
0 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-03-01 |
4 |
AS |
$759.89 |
$835,879 |
D/D |
(1,100) |
20,803 |
|
-7% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-03-01 |
4 |
OE |
$372.46 |
$409,706 |
D/D |
1,100 |
21,903 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2023-03-01 |
4 |
AS |
$758.20 |
$76,250 |
D/D |
(100) |
19,147 |
|
-7% |
|
| Vagelos P Roy |
Director |
– • – |
2023-02-22 |
4 |
D |
$750.16 |
$21,758,391 |
D/D |
(29,005) |
337,578 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2023-02-22 |
4 |
OE |
$270.43 |
$11,493,275 |
D/D |
42,500 |
366,583 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-02-12 |
4 |
D |
$751.78 |
$959,271 |
D/D |
(1,276) |
20,803 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-02-07 |
4 |
S |
$769.04 |
$769,040 |
D/D |
(1,000) |
22,079 |
|
-2% |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2023-02-07 |
4 |
OE |
$372.46 |
$372,460 |
D/D |
1,000 |
23,079 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2023-02-06 |
4 |
AS |
$800.08 |
$10,552,255 |
I/I |
(13,189) |
200,504 |
|
0% |
|
| Goldstein Joseph L |
Director |
– • – |
2023-02-06 |
4 |
AS |
$800.00 |
$2,890,400 |
D/D |
(3,613) |
6,247 |
|
0% |
|
| Goldstein Joseph L |
Director |
– • – |
2023-02-06 |
4 |
OE |
$482.68 |
$1,743,923 |
D/D |
3,613 |
9,860 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2023-02-06 |
4 |
AS |
$797.00 |
$398,500 |
I/I |
(500) |
6,162 |
|
0% |
|
| Brown Michael S |
Director |
– • – |
2023-02-06 |
4 |
AS |
$798.00 |
$2,450,658 |
D/D |
(3,071) |
1,247 |
|
0% |
|
| Brown Michael S |
Director |
– • – |
2023-02-06 |
4 |
OE |
$520.01 |
$1,596,951 |
D/D |
3,071 |
4,318 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-02-06 |
4 |
AS |
$783.05 |
$593,238 |
D/D |
(752) |
32,105 |
|
0% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-02-03 |
4 |
D |
$774.29 |
$1,740,604 |
D/D |
(2,248) |
32,857 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2023-02-03 |
4 |
OE |
$381.92 |
$1,145,760 |
D/D |
3,000 |
35,105 |
|
- |
|
1366 Records found
|
|
Page 8 of 55 |
|
|
7.48 (0.84%) 
